BAFFR/TNFRSF13C[Biotin], His & Avi, Human
BAFFR/TNFRSF13C[Biotin], His & Avi, Human

BAFFR/TNFRSF13C[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced conditions. The purity is greater than 95%.

BAFFR/TNFRSF13C[Biotin], His & Avi, Human

Immobilized Anti-BAFFR Antibody, hFc Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for BAFFR/TNFRSF13C[Biotin], His & Avi, Human, His Tag with the EC50 of 5.5ng/ml determined by ELISA.

BAFFR/TNFRSF13C[Biotin], His & Avi, Human

Immobilized Human BAFF (Trimer), His Tag at 5 μg/ml (100 μl/well) on the plate. Dose response curve for BAFFR/TNFRSF13C[Biotin], His & Avi, Human, His Tag with the EC50 of 57.9ng/ml determined by ELISA.

BAFFR/TNFRSF13C[Biotin], His & Avi, Human

BAFF binds to three TNF receptor superfamily members: B-cell maturation antigen (BCMA/TNFRSF17), transmembrane activator and calcium-modulator and cyclophilin ligand interactor (TACI/TNFRSF13B) and BAFF receptor (BAFF R/BR3/TNFRSF13C). These receptors are type III transmembrane proteins that lack a signal peptide. Whereas TACI and BCMA bind BAFF and another TNF superfamily ligand, APRIL (a proliferation-inducing ligand), BAFF R selectively binds BAFF.
Z04414
¥123,118.00

Ask us a question
Product Introduction
Species Human
Protein Construction
BAFFR/TNFRSF13C (Ser7-Ala71)
Accession # Q96RJ3-1		 His Avi
N-term C-term
Conjugate Biotin
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 9.5 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 20-25 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • BAFFR/TNFRSF13C[Biotin], His & Avi, Human
    • BAFFR/TNFRSF13C[Biotin], His & Avi, Human

    BAFFR/TNFRSF13C[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced conditions. The purity is greater than 95%.

  • BAFFR/TNFRSF13C[Biotin], His & Avi, Human
    • BAFFR/TNFRSF13C[Biotin], His & Avi, Human

    Immobilized Anti-BAFFR Antibody, hFc Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for BAFFR/TNFRSF13C[Biotin], His & Avi, Human, His Tag with the EC50 of 5.5ng/ml determined by ELISA.

  • BAFFR/TNFRSF13C[Biotin], His & Avi, Human
    • BAFFR/TNFRSF13C[Biotin], His & Avi, Human

    Immobilized Human BAFF (Trimer), His Tag at 5 μg/ml (100 μl/well) on the plate. Dose response curve for BAFFR/TNFRSF13C[Biotin], His & Avi, Human, His Tag with the EC50 of 57.9ng/ml determined by ELISA.


Background
Target Background BAFF binds to three TNF receptor superfamily members: B-cell maturation antigen (BCMA/TNFRSF17), transmembrane activator and calcium-modulator and cyclophilin ligand interactor (TACI/TNFRSF13B) and BAFF receptor (BAFF R/BR3/TNFRSF13C). These receptors are type III transmembrane proteins that lack a signal peptide. Whereas TACI and BCMA bind BAFF and another TNF superfamily ligand, APRIL (a proliferation-inducing ligand), BAFF R selectively binds BAFF.
Synonyms CD268; BAFFR; BR3; TNFRSF13C; BROMIX; CVID4; prolixin

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.